These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12467763)

  • 1. Global epidemiology and burden of hepatitis C.
    Ray Kim W
    Microbes Infect; 2002 Oct; 4(12):1219-25. PubMed ID: 12467763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The global burden of hepatitis C.
    Lavanchy D
    Liver Int; 2009 Jan; 29 Suppl 1():74-81. PubMed ID: 19207969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C.
    Lavanchy D; Gavinio P
    Can J Gastroenterol; 2000; 14 Suppl B():67B-76B. PubMed ID: 10938509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mobilising a global response to hepatitis: Lessons learned from the HIV movement.
    Taaffe J; Wilson D
    Glob Public Health; 2018 Apr; 13(4):473-488. PubMed ID: 27748158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost of hepatitis C and the cost-effectiveness of its prevention.
    Shiell A; Law MG
    Health Policy; 2001 Nov; 58(2):121-31. PubMed ID: 11551662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology of hepatitis C infection and its public health implications in Puerto Rico.
    Pérez CM; Suárez E; Torres EA
    P R Health Sci J; 2004 Jun; 23(2 Suppl):11-28. PubMed ID: 16929583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.
    J Viral Hepat; 1999 Jan; 6(1):35-47. PubMed ID: 10847128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern.
    Van Nuys K; Brookmeyer R; Chou JW; Dreyfus D; Dieterich D; Goldman DP
    Health Aff (Millwood); 2015 Oct; 34(10):1666-74. PubMed ID: 26438742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
    PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economics of hepatitis C virus.
    Shah BB; Wong JB
    Clin Liver Dis; 2006 Nov; 10(4):717-34. PubMed ID: 17164114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
    Scott N; McBryde ES; Thompson A; Doyle JS; Hellard ME
    Gut; 2017 Aug; 66(8):1507-1515. PubMed ID: 27196586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global burden of hepatitis C: considerations for healthcare providers in the United States.
    Averhoff FM; Glass N; Holtzman D
    Clin Infect Dis; 2012 Jul; 55 Suppl 1():S10-5. PubMed ID: 22715208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic burden of hepatitis C-associated diseases in the United States.
    El Khoury AC; Klimack WK; Wallace C; Razavi H
    J Viral Hepat; 2012 Mar; 19(3):153-60. PubMed ID: 22329369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hepatitis B and hepatitis C, a high stake for public health: how to reconcile health cost control and public health expenses?].
    Allerg Immunol (Paris); 1997 Sep; 29(7):215-8. PubMed ID: 9432191
    [No Abstract]   [Full Text] [Related]  

  • 16. Economic burden associated with patients diagnosed with hepatitis C.
    McCombs JS; Yuan Y; Shin J; Saab S
    Clin Ther; 2011 Sep; 33(9):1268-80. PubMed ID: 21840056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.
    Bruggmann P; Grebely J
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S22-6. PubMed ID: 25245939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment costs of hepatitis C infection among injection drug users in Canada, 2006-2026.
    Werb D; Wood E; Kerr T; Hershfield N; Palmer RW; Remis RS
    Int J Drug Policy; 2011 Jan; 22(1):70-6. PubMed ID: 21051212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burden of illness of hepatitis C from a managed care organization perspective.
    Armstrong EP; Charland SL
    Curr Med Res Opin; 2004 May; 20(5):671-9. PubMed ID: 15140332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C: public health strategies.
    Lavanchy D
    J Hepatol; 1999; 31 Suppl 1():146-51. PubMed ID: 10622578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.